Fred Hutch Cancer Center | Strategic Alliance Partners

Latest from Fred Hutch Cancer Center


Nab-Paclitaxel Therapy in Pancreatic Cancer Deemed Patient Friendly

March 28, 2014

A recently approved indication for nab-paclitaxel (Abraxane) in metastatic pancreatic cancer is thought to have similar efficacy to a standard first-line treatment for the disease, but offers several advantages in the eyes of community oncologists and their patients

Idelalisib Shows Promising Activity in Heavily Pretreated iNHL

February 26, 2014

Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with an average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin's lymphoma.

Dr. Yu Discusses the Utility of GTx-758 in mCRPC

February 24, 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.

Dr. Yu Discusses Optimal Testosterone Suppression

February 06, 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

Hematologic Immunotherapy Breaks New Ground in Established Field

December 06, 2013

Although immunotherapy advances in solid tumors have captured much attention in recent years, therapeutic strategies that enable the patient's own immune system to battle cancer cells have long been integrated into the treatment of patients with hematologic malignancies.

Dr. Grady on Gene Profiling of CTCs in Pancreatic Cancer

March 07, 2013

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.